Citigroup’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.26K | Buy |
3,111
+1,556
| +100% | +$6.82K | ﹤0.01% | 5253 |
|
|
2025
Q4 | $8.05K | Sell |
1,555
-1,453
| -48% | -$7.46K | ﹤0.01% | 5123 |
|
|
2025
Q3 | $15.7K | Sell |
3,008
-44,742
| -94% | -$233K | ﹤0.01% | 4889 |
|
|
2025
Q2 | $183K | Buy |
47,750
+13,088
| +38% | +$33.8K | ﹤0.01% | 4114 |
|
|
2025
Q1 | $199K | Sell |
34,662
-3,932
| -10% | -$23.2K | ﹤0.01% | 4203 |
|
|
2024
Q4 | $193K | Buy |
38,594
+2,302
| +6% | +$11.8K | ﹤0.01% | 4436 |
|
|
2024
Q3 | $196K | Buy |
36,292
+25,089
| +224% | +$119K | ﹤0.01% | 4357 |
|
|
2024
Q2 | $37.1K | Buy |
11,203
+3,401
| +44% | +$13.3K | ﹤0.01% | 4751 |
|
|
2024
Q1 | $25.5K | Buy |
7,802
+1,376
| +21% | +$4.53K | ﹤0.01% | 4954 |
|
|
2023
Q4 | $22.6K | Sell |
6,426
-106,610
| -94% | -$329K | ﹤0.01% | 4946 |
|
|
2023
Q3 | $755K | Buy |
113,036
+29,031
| +35% | +$215K | ﹤0.01% | 2739 |
|
|
2023
Q2 | $705K | Buy |
84,005
+35,419
| +73% | +$349K | ﹤0.01% | 3112 |
|
|
2023
Q1 | $482K | Buy |
48,586
+3,766
| +8% | +$26.6K | ﹤0.01% | 3155 |
|
|
2022
Q4 | $312K | Buy |
44,820
+39,808
| +794% | +$228K | ﹤0.01% | 3486 |
|
|
2022
Q3 | $27K | Sell |
5,012
-361,218
| -99% | -$2.17M | ﹤0.01% | 4623 |
|
|
2022
Q2 | $1.46M | Buy |
366,230
+364,485
| +20,887% | +$1.25M | ﹤0.01% | 2344 |
|
|
2022
Q1 | $8K | Sell |
1,745
-171,317
| -99% | -$682K | ﹤0.01% | 5622 |
|
|
2021
Q4 | $692K | Buy |
173,062
+77,916
| +82% | +$594K | ﹤0.01% | 3583 |
|
|
2021
Q3 | $835K | Sell |
95,146
-116,650
| -55% | -$1.07M | ﹤0.01% | 3222 |
|
|
2021
Q2 | $2.4M | Sell |
211,796
-19,695
| -9% | -$237K | ﹤0.01% | 2525 |
|
|
2021
Q1 | $2.75M | Buy |
231,491
+187,298
| +424% | +$2.16M | ﹤0.01% | 2267 |
|
|
2020
Q4 | $303K | Buy |
44,193
+21,535
| +95% | +$151K | ﹤0.01% | 4646 |
|
|
2020
Q3 | $168K | Buy |
22,658
+16,559
| +272% | +$107K | ﹤0.01% | 4740 |
|
|
2020
Q2 | $25K | Sell |
6,099
-5,300
| -46% | -$19.4K | ﹤0.01% | 6428 |
|
|
2020
Q1 | $28K | Buy |
11,399
+2,101
| +23% | +$9.45K | ﹤0.01% | 6444 |
|
|
2019
Q4 | $54K | Buy |
9,298
+3,649
| +65% | +$21.1K | ﹤0.01% | 6234 |
|
|
2019
Q3 | $30K | Sell |
5,649
-1,509
| -21% | -$8.12K | ﹤0.01% | 6456 |
|
|
2019
Q2 | $43K | Buy |
7,158
+424
| +6% | +$3.19K | ﹤0.01% | 6599 |
|
|
2019
Q1 | $61K | Buy |
6,734
+1,428
| +27% | +$12.1K | ﹤0.01% | 6166 |
|
|
2018
Q4 | $44K | Sell |
5,306
-1,015,916
| -99% | -$10.4M | ﹤0.01% | 6330 |
|
|
2018
Q3 | $14.1M | Buy |
1,021,222
+1,018,934
| +44,534% | +$8.27M | 0.01% | 1063 |
|
|
2018
Q2 | $18K | Buy |
+2,288
| New | +$18.3K | ﹤0.01% | 6960 |
|
|
2016
Q2 | – | Sell |
-4
| Closed | – | – | 7046 |
|
|
2016
Q1 | $0 | Buy |
+4
| New | +$19 | ﹤0.01% | 7431 |
|
|
2014
Q4 | – | Sell |
-42
| Closed | – | – | 7092 |
|
|
2014
Q3 | $0 | Buy |
+42
| New | +$204 | ﹤0.01% | 7041 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Citigroup's ALDX Position: Q1 2026 in Review
Citigroup increased its Aldeyra Therapeutics (ALDX) stake by 100% in Q1 2026, buying an estimated $6.82K and bringing the position to 3,111 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #5253.
Citigroup first reported a position in ALDX in Q3 2014 and has held it in 34 quarters since. The position peaked at $14.1M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Citigroup held 3,111 shares of Aldeyra Therapeutics worth $5.26K as of Q1 2026.
- Citigroup bought 1,556 Aldeyra Therapeutics shares in Q1 2026, an estimated $6.82K.
- Aldeyra Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5253 holding.
- Citigroup first reported a position in Aldeyra Therapeutics in Q3 2014 and has held it in 34 quarters since.
- Citigroup's Aldeyra Therapeutics position peaked at $14.1M in Q3 2018.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.